New Safety and Long-Term Efficacy Data from Baricitinib Clinical Trials in Patients with Moderate-to-Severe Rheumatoid Arthritis Presented at EULAR 2017

Pooled analysis of eight clinical trials shows no difference in serious infection events compared to placebo Results from long-term extension of Phase 3 studies show treatment with baricitinib slows the progression of joint damage and controls disease a... Biopharmaceuticals Eli Lilly, Incyte , Olumiant, baricitinib, rheumatoid arthritis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news